ChemicalBook > Product Catalog >Biochemical Engineering >Antibody >Tezepelumab

Tezepelumab

Tezepelumab Suppliers list
Company Name: Wuhan Sunrise Technology Development Co., Ltd.  
Tel: 27-027-83314682 13554138826
Email: whsrtech@vip.163.com
Company Name: Nanjing Sunlida Biological Technology Co., Ltd.  
Tel: 025-57798810 18652991625
Email: sales@sunlidabio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Hefei Hirisun Pharmatech Co., Ltd.  
Tel: +86-0551-62678551 15056975894
Email: sales@hirisunpharm.com
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com

Tezepelumab manufacturers

  • Tezepelumab
  • Tezepelumab pictures
  • $263.00
  • 2026-07-31
  • CAS:1572943-04-4
  • Purity: 95.00%
  • Supply Ability: 10g
Tezepelumab Basic information
Product Name:Tezepelumab
Synonyms:Tezepelumab;Research Grade Tezepelumab(DHJ36101);Tezepelumab-ekko|||MEDI 19929|||AMG 157;Research Grade Tezepelumab;Tezepelumab (anti-TSLP)
CAS:1572943-04-4
MF:
MW:0
EINECS:
Product Categories:
Mol File:Mol File
Tezepelumab Structure
Tezepelumab Chemical Properties
form Liquid
color Colorless to light yellow
Safety Information
MSDS Information
Tezepelumab Usage And Synthesis
UsesTezepelumab (anti-TSLP) is human monoclonal antibody (IgG2λ) that binds specifically to TSLP, blocking it from interacting with its heterodimeric receptor. Tezepelumab can be used for the research of severe, uncontrolled asthma[1].
References[1] Menzies-Gow A, et, al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N Engl J Med. 2021 May 13;384(19):1800-1809. DOI:10.1056/NEJMoa2034975
Tezepelumab Preparation Products And Raw materials
Tag:Tezepelumab(1572943-04-4) Related Product Information
MilatuzuMab Immunoglobulin G 1 (human-mouse monoclonal BIWA4 gamma1-chain antihuman antigen CD44v8), disulfide with human-mouse monoclonal BIWA4 gamma-chain, dimer Marstacimab Cinpanemab Diridavumab Olaratumab Teplizumab Narnatumab Zalutumumab abciximab